Results 81 to 90 of about 695,469 (357)

A mammalian Wnt5a-Ror2-Vangl2 axis controls the cytoskeleton and confers cellular properties required for alveologenesis. [PDF]

, 2020
Alveolar formation increases the surface area for gas-exchange and is key to the physiological function of the lung. Alveolar epithelial cells, myofibroblasts and endothelial cells undergo coordinated morphogenesis to generate epithelial folds (secondary
Chou, Yu-Ting, Chuang, Pao-Tien, Li, Jianying, Lin, Chuwen, Wolters, Paul J, Wong, Julia, Yao, Erica, Zhang, Kuan   +7 more
core   +1 more source

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management

Current Medical Research and Opinion, 2019
Objective: Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) develop a progressive fibrosing phenotype.
M. Wijsenbeek, M. Kreuter, A. Olson, A. Fischer, E. Bendstrup, C. Wells, C. Denton, B. Mounir, L. Zouad-Lejour, M. Quaresma, V. Cottin   +10 more
semanticscholar   +1 more source

LOXHD1 and RHOB Expression by Monocytes Predicts Progressive Systemic Sclerosis associated Interstitial Lung Disease

Arthritis Care &Research, Accepted Article.
Objective A leading cause of death among scleroderma (SSc) patients, interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M Padilla, Robert Lafyatis, Kevin F Gibson, Christina Morse, Eleanor Valenzi, Xiaoping Chen, Xiaoyun Li, Yanwu Zhao, Yongseok Park, Dana Ascherman, Jonathan Minden, Robyn Domsic, Yingze Zhang, Daniel J Kass   +13 more
wiley   +1 more source

99mTc-MIBI Lung Scintigraphy in the Assessment of Pulmonary Involvement in Interstitial Lung Disease and Its Comparison With Pulmonary Function Tests and High-Resolution Computed Tomography: A Preliminary Study [PDF]

, 2015
The differentiation of active inflammatory processes from an inactive form of the disease is of great value in the management of interstitial lung disease (ILD).
Assadi, M., Bahtouee, M., Eftekhari, M., Javadi, H., Nabipour, I., Raeisi, A., Saberifard, J.   +6 more
core   +2 more sources

Pharmacogenetics and interstitial lung disease [PDF]

Current Opinion in Pulmonary Medicine, 2016
Interstitial lung disease (ILD) is comprised of a heterogeneous group of disorders with highly variable natural histories and response to therapies. Pharmacogenetics focuses on the variability in drug response because of the presence of genetic factors that influence drug metabolism or disease activity. In this article, we review relevant drug-specific
Oldham, Justin M, Noth, Imre, Martinez, Fernando J   +2 more
openaire   +4 more sources

Heterogeneity of Rheumatoid Arthritis–Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes

Arthritis Care &Research, EarlyView.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999 to 2021.
Bryant R. England, Yangyuna Yang, Punyasha Roul, Tate M. Johnson, Scott M. Matson, Grant W. Cannon, Brian C. Sauer, Jeffrey R. Curtis, Joshua F. Baker, Ted R. Mikuls   +9 more
wiley   +1 more source

The natural history of progressive fibrosing interstitial lung diseases

Respiratory Research, 2019
A proportion of patients with certain types of interstitial lung disease (ILD), including chronic hypersensitivity pneumonitis and ILDs associated with autoimmune diseases, develop a progressive fibrosing phenotype that shows similarities in clinical ...
M. Kolb, M. Vašáková
semanticscholar   +1 more source

Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States

Arthritis Care &Research, EarlyView.
Objective There are no US Food and Drug Administration–approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient‐reported outcome measures and mechanistic quantification allow RP‐related pain characterization.
Tracy M. Frech, Charles G. Frech, W. David Merryman, Andrew Sternlicht, Justin Baba   +4 more
wiley   +1 more source

Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations [PDF]

, 2014
BACKGROUND: Previous studies investigating a genetic basis for idiopathic pulmonary fibrosis (IPF) have focused on resequencing single genes in IPF kindreds or cohorts to determine the genetic contributions to IPF.
Coghlan, Meghan A, Cole, F. Sessions, Hamvas, Aaron, Huang, Howard J, Mitra, Robi D, Russell, Tonya D, Shifren, Adrian, Wegner, Daniel J, Zhang, Qunyuan   +8 more
core   +3 more sources

Fibrosing interstitial lung diseases: knowns and unknowns

European Respiratory Review, 2019
Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function, worsening quality of life, and early mortality.
V. Cottin, L. Wollin, A. Fischer, M. Quaresma, S. Stowasser, S. Harari   +5 more
semanticscholar   +1 more source